Annual report
2160.TEDINET S100VJ7H
Period2024-01-01 → 2024-12-31
Filed2025-03-31
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 147
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥23.6bn | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥26.0bn | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥17.4bn | 2022-01-01 → 2022-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥12.7bn | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥9.8bn | 2020-01-01 → 2020-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥1.4bn | 2024-01-01 → 2024-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥13.1bn | 2023-01-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥238m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥12.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥768m | 2022-01-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.1bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.8bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥1.1bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥8.1bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥389m | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.1bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.3bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | −¥10m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥9.5bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Net income | −¥868m | 2022-01-01 → 2022-12-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥55m | 2021-01-01 → 2021-12-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥1.4bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥71.9bn | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥64.3bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥33.9bn | at 2022-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥30.3bn | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥23.2bn | at 2020-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥32.2bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥27.8bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥39.7bn | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥36.5bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥36.4bn | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥33.8bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥21.0bn | at 2022-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥18.9bn | at 2021-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥11.0bn | at 2020-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥10.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.6bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.0bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.4bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥10.3bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | −¥3.2bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥6.5bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥393m | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥552m | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.4bn | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥10.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥6.8bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥4.1bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥261m | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥570m | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥694m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥10.7bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥646m | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥2.9bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥801m | 2020-01-01 → 2020-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥21.96 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥169.5 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥8.19 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥22.72 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥28.96 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥21.15 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥165.56 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥8.11 | 2022-01-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥22.08 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥28.04 | 2020-01-01 → 2020-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥726.67 | at 2024-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥678.01 | at 2023-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥441.59 | at 2022-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥397.38 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥252.8 | at 2020-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 50.7% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 52.6% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.8% | at 2022-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.3% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 47.4% | at 2020-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 3.1% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 29.6% | 2023-01-01 → 2023-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 2.0% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.1% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.6% | 2020-01-01 → 2020-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 867 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 843 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 701 | at 2022-12-31d | Cons. | Number of employees |
| Employees | 629 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 539 | at 2020-12-31d | Cons. | Number of employees |
| Revenue | ¥24m | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥22m | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥22m | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥225m | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥356m | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥658m | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | −¥562m | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | ¥5.9bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥31m | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥552m | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥436m | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥170m | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.9bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥9m | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | ¥5.9bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | −¥1.0bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥438m | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥171m | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥39.9bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥30.6bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥15.5bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥16.5bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.8bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥15.9bn | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥12.9bn | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥24.1bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥17.7bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥14.6bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥15.7bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥10.9bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.5bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.8bn | at 2023-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥118.06 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-21.92 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-25.5 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-9.33 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.94 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥113.7 | 2024-01-01 → 2024-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥480.08 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥355.54 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥306.75 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥329.22 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥248.93 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 60.2% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.8% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.0% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.5% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.8% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 28.2% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 50,168,243 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 49,857,243 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 47,487,843 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 47,462,943 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 43,513,149 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 15 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 10 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 9 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 7 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 6 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| Medical Devicereportable segment | employees | at 2024-12-31 | 111 pure |
| Medical Devicereportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥5.3bn |
| Medical Devicereportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥5.3bn |
| Medical Devicereportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥1.0bn |
| Pharmaceuticalreportable segment | employees | at 2024-12-31 | 756 pure |
| Pharmaceuticalreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥18.3bn |
| Pharmaceuticalreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥18.3bn |
| Pharmaceuticalreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥371m |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥23.6bn |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥23.6bn |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥1.4bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-12-31 | −¥24m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-12-31 | −¥24m |
| Medical Devicereportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥3.1bn |
| Medical Devicereportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥3.0bn |
| Medical Devicereportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥24m |
| Medical Devicereportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥1.1bn |
| Pharmaceuticalreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥23.0bn |
| Pharmaceuticalreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥23.0bn |
| Pharmaceuticalreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥12.0bn |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥26.0bn |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥26.0bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥24m |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥13.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,813
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from purchase of shares of subsidiaries resulting in change in scope of consolidation inv cf IFRS | Prior1YearDuration | 954505000 | JPY |
| Proceeds from purchase of shares of subsidiaries resulting in change in scope of consolidation inv cf IFRS | CurrentYearDuration | － | JPY |
| Payments for acquisition of businesses inv cf IFRS | Prior1YearDuration | -2047274000 | JPY |
| Payments for acquisition of businesses inv cf IFRS | CurrentYearDuration | － | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YearDuration | -6842661000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYearDuration | -10361330000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | Prior1YearDuration | 1100000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYearDuration | 3275000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YearDuration | 2000000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYearDuration | － | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YearDuration | － | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYearDuration | -400000000 | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | Prior1YearDuration | 4287054000 | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | CurrentYearDuration | 727324000 | JPY |
| Proceeds from issuance of share acquisition rights fin cf IFRS | Prior1YearDuration | 798000 | JPY |
| Proceeds from issuance of share acquisition rights fin cf IFRS | CurrentYearDuration | 326000 | JPY |
| Capital contribution from non controlling interests fin cf IFRS | Prior1YearDuration | 3516749000 | JPY |
| Capital contribution from non controlling interests fin cf IFRS | CurrentYearDuration | 741982000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | Prior1YearDuration | － | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | CurrentYearDuration | -3269100000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1YearDuration | -38000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | CurrentYearDuration | -69000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YearDuration | -218008000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYearDuration | -381303000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YearDuration | 10686556000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYearDuration | 694161000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YearDuration | 190485000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYearDuration | 1313601000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YearDuration | 10583717000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYearDuration | -11517990000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 11049310000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 21633028000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 21633028000 | JPY |
| Cash and cash equivalents IFRS | CurrentYearInstant | 10115037000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E05712-000PharmaceuticalReportableSegmentMember | 22976201000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E05712-000MedicalDeviceReportableSegmentMember | 3034369000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReportableSegmentsMember | 26010571000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | Prior1YearDuration | 26010571000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E05712-000PharmaceuticalReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E05712-000MedicalDeviceReportableSegmentMember | 24171000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_ReportableSegmentsMember | 24171000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration_ReconcilingItemsMember | -24171000 | JPY |
| Intersegment revenue IFRS | Prior1YearDuration | － | JPY |
| Revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E05712-000PharmaceuticalReportableSegmentMember | 22976201000 | JPY |
| Revenue IFRS | Prior1YearDuration_jpcrp030000-asr_E05712-000MedicalDeviceReportableSegmentMember | 3058541000 | JPY |
| Revenue IFRS | Prior1YearDuration_ReportableSegmentsMember | 26034742000 | JPY |
| Revenue IFRS | Prior1YearDuration_ReconcilingItemsMember | -24171000 | JPY |
| Revenue IFRS | Prior1YearDuration | 26010571000 | JPY |
| Operating profit loss IFRS | Prior1YearDuration_jpcrp030000-asr_E05712-000PharmaceuticalReportableSegmentMember | 12026795000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |